The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...

US company IDEAYA Biosciences has exercised the option for an exclusive worldwide license for Biocytogen Pharmaceuticals’ ...

The US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) today launched new advertisements urging ...

The US Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III ...

Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director ...

The combination of Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) and Citius Pharmaceuticals’ (Nasdaq: CTXR) Lymphir ...

Geron Corporation has secured $375 million to support the US and potential EU launch of Rytelo and pipeline development. The ...

Aurinia Pharmaceuticals (Nasdaq: AUPH) has announced a major strategic overhaul, reducing its workforce by almost half to focus on driving Lupkynis (voclosporin) growth. The changes, which will also ...

Almirall (BME: ALM), the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 ...

Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi ...